Figure 9.

Efficacy of combination treatment of TF-TCB and nivolumab in NCI-H292 xenograft model with intravenous transfer of PBMC. (A) Schematic depiction of tumor inoculation and treatment protocol. Female NOG mice were implanted s.c. with 3 × 10⁶ NCI-H292 cells on Day 0. On Day 3, 5 × 10⁶ PBMC were injected i.v. into mice. On Days 9–24, mice were divided into four groups (n = 8/group) based on tumor volume and treated with PBS (i.v.), TF-TCB (5 mg/kg, i.v.), nivolumab (10 mg/kg, i.p.) or combination of TF-TCB (5 mg/kg, i.v.) and nivolumab (10 mg/kg, i.p.). (B) Tumor volume of individual mice in each group measured throughout the study. (C) Tumor volume of four groups. (D) Digital image and weight of the stripped tumors (one mice in the PBS and TF-TCB + nivolumab group, three mice in the nivolumab group died before study ended). (E) Percentage of human CD45⁺ cells in mice peripheral blood 14 days after PBMC transfer. Statistical analysis was based on two-tailed heteroscedastic t-test. ∗∗∗P < 0.0001 vs. PBS group; ^###P < 0.0001 vs. Nivolumab group; ^$P < 0.05 vs. TF-TCB group. Data are mean ± SD, n = 8.